Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Mehra

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2024
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trialS van Wilpe, I S H Kloots, P H J Slootbeek, et al.
Prostate Cancer and Prostatic Diseases|March 22, 2021
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world populationH M Westgeest, M C P Kuppen, A J M van den Eertwegh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2020
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancerM P Kolinsky, P Rescigno, D Bianchini, et al.
Clinical Transplants|July 22, 2008
14th International HLA and Immunogenetics Workshop Prospective Chronic Rejection Project: a three-year follow-up analysisM Ozawa, P I Terasaki, R Castro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2026
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upK Fizazi, G Attard, A A Azad, et al.
Nature|October 2, 2019
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugsD L van der Velden, L R Hoes, H van der Wijngaart, et al.
Tissue Antigens|April 21, 2007
14th International HLA and Immunogenetics Workshop: report on the Prospective Chronic Rejection ProjectM Ozawa, P I Terasaki, J H Lee, et al.
International Journal of Immunogenetics|January 3, 2013
16(th) IHIW: analysis of HLA population data, with updated results for 1996 to 2012 workshop data (AHPD project report)M E Riccio, S Buhler, J M Nunes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 29, 2025
Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancerT Virtanen, E M Kwan, K Parekh, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2024
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trialS van Wilpe, I S H Kloots, P H J Slootbeek, et al.
Prostate Cancer and Prostatic Diseases|March 22, 2021
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world populationH M Westgeest, M C P Kuppen, A J M van den Eertwegh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2020
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancerM P Kolinsky, P Rescigno, D Bianchini, et al.
Clinical Transplants|July 22, 2008
14th International HLA and Immunogenetics Workshop Prospective Chronic Rejection Project: a three-year follow-up analysisM Ozawa, P I Terasaki, R Castro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2026
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upK Fizazi, G Attard, A A Azad, et al.
Nature|October 2, 2019
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugsD L van der Velden, L R Hoes, H van der Wijngaart, et al.
Tissue Antigens|April 21, 2007
14th International HLA and Immunogenetics Workshop: report on the Prospective Chronic Rejection ProjectM Ozawa, P I Terasaki, J H Lee, et al.
International Journal of Immunogenetics|January 3, 2013
16(th) IHIW: analysis of HLA population data, with updated results for 1996 to 2012 workshop data (AHPD project report)M E Riccio, S Buhler, J M Nunes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 29, 2025
Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancerT Virtanen, E M Kwan, K Parekh, et al.
Pageof 8